Patients with Diffuse Large B-Cell Lymphoma
We Need Your Help!
Lymphoma Canada is preparing a submission for the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Quebec equivalent INESSS (Institut national d’excellence en santé et services sociaux), for an upcoming drug review on Glofitamab.
Glofitamab (also known as Columvi) is a CD20 x CD3 bispecific antibody which recruits T cells to tumor cells. This treatment is being submitted for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma or primary mediastinal B-cell lymphoma (PMBL) who have received two or more lines of systemic therapy and are ineligible or cannot receive CAR T cell therapy or have previously received CAR T-cell therapy.
If you have DLBCL and have received this treatment, you can help by completing our survey! You can still participate in this survey if you have not received this therapy. You do not need to have relapsed or refractory DLBCL to participate.
The survey provides us with patient input required for the submission. CADTH uses this information to help make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Friday, July 21, 2023, and should only take between 15-20 minutes of your time.
Please share and help us spread the word.
Thank you for your support.
Follow us on Social Media to stay up to date and informed on all things Lymphoma Canada!
